JP2019535677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535677A5 JP2019535677A5 JP2019521662A JP2019521662A JP2019535677A5 JP 2019535677 A5 JP2019535677 A5 JP 2019535677A5 JP 2019521662 A JP2019521662 A JP 2019521662A JP 2019521662 A JP2019521662 A JP 2019521662A JP 2019535677 A5 JP2019535677 A5 JP 2019535677A5
- Authority
- JP
- Japan
- Prior art keywords
- msc
- prostacyclin
- exposed
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001123 epoprostenol Drugs 0.000 claims description 52
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims description 52
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 46
- 230000014509 gene expression Effects 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 24
- 210000001808 exosome Anatomy 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- 229960005032 treprostinil Drugs 0.000 claims description 11
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 7
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims description 7
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 7
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 7
- 102000003814 Interleukin-10 Human genes 0.000 claims description 7
- 108090000174 Interleukin-10 Proteins 0.000 claims description 7
- 102000003816 Interleukin-13 Human genes 0.000 claims description 7
- 108090000176 Interleukin-13 Proteins 0.000 claims description 7
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 7
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 7
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 7
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 6
- 206010059245 Angiopathy Diseases 0.000 claims description 5
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 108700011259 MicroRNAs Proteins 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 210000003470 mitochondria Anatomy 0.000 claims description 4
- 108091027963 non-coding RNA Proteins 0.000 claims description 4
- 102000042567 non-coding RNA Human genes 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 3
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims 2
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411950P | 2016-10-24 | 2016-10-24 | |
| US62/411,950 | 2016-10-24 | ||
| PCT/US2017/057863 WO2018080990A1 (en) | 2016-10-24 | 2017-10-23 | Enhancement of msc immunomodulatory properties by treprostinil |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535677A JP2019535677A (ja) | 2019-12-12 |
| JP2019535677A5 true JP2019535677A5 (enExample) | 2020-11-26 |
| JP7179723B2 JP7179723B2 (ja) | 2022-11-29 |
Family
ID=60570174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521662A Active JP7179723B2 (ja) | 2016-10-24 | 2017-10-23 | トレプロスチニルによるｍｓｃの免疫調節特性の増強 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11571444B2 (enExample) |
| EP (1) | EP3534917B1 (enExample) |
| JP (1) | JP7179723B2 (enExample) |
| KR (1) | KR102606101B1 (enExample) |
| CN (1) | CN110177559A (enExample) |
| AU (1) | AU2017350732B2 (enExample) |
| CA (1) | CA3041514A1 (enExample) |
| ES (1) | ES2927406T3 (enExample) |
| IL (1) | IL266175B2 (enExample) |
| WO (1) | WO2018080990A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2869701T3 (es) | 2012-08-01 | 2021-10-25 | United Therapeutics Corp | Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina |
| AU2014205557B2 (en) | 2013-01-09 | 2017-08-10 | United Therapeutics Corporation | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells |
| AU2019283518B2 (en) * | 2018-06-05 | 2025-09-11 | Medipost Co., Ltd. | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
| KR20210089659A (ko) | 2018-10-05 | 2021-07-16 | 제노세라퓨틱스, 인코포레이티드 | 이종이식 생성물 및 방법 |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| CN113056278A (zh) | 2018-10-18 | 2021-06-29 | 南特生物公司 | 间充质干细胞来源的外泌体和方法 |
| CN113274411A (zh) * | 2021-04-21 | 2021-08-20 | 西安市第一医院 | 经基因修饰的骨髓间充质干细胞来源的微囊泡在制备治疗肾损伤药物中的应用 |
| CN118576532B (zh) * | 2024-08-05 | 2024-11-26 | 北京青藤谷禧干细胞科技研究院有限公司 | 一种含干细胞外泌体的面部美容组合物及其制备方法和应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3089815A (en) | 1951-10-11 | 1963-05-14 | Lieb Hans | Injectable pharmaceutical preparation, and a method of making same |
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
| US5130144B1 (en) | 1984-02-06 | 1995-08-15 | Univ Johns Hopkins | Human stem cells and monoclonal antibodies |
| US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
| US5026365A (en) | 1987-04-29 | 1991-06-25 | The University Of Massachusetts | Method and apparatus for therapeutically treating immunological disorders and disease states |
| US4983393A (en) | 1987-07-21 | 1991-01-08 | Maximed Corporation | Intra-vaginal device and method for sustained drug release |
| ATE81724T1 (de) | 1987-11-09 | 1992-11-15 | Becton Dickinson Co | Verfahren zur analyse haematopoietischer zellen in einer probe. |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5071741A (en) | 1988-04-18 | 1991-12-10 | Cryolife, Inc. | Cryoprotective agent and its use in cryopreservation of cellular matter |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5283058A (en) | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| WO1993014191A1 (en) | 1992-01-21 | 1993-07-22 | Cryopharm Corporation | Method of freezing cells and cell-like materials |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| SG48813A1 (en) | 1993-08-12 | 1998-05-18 | Cytotherapeutics Inc | Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US5518878A (en) | 1993-09-15 | 1996-05-21 | Organogenesis Inc. | Cryopreservation of cultured skin or cornea equivalents with agitation |
| US5693531A (en) | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
| DE69530914T2 (de) | 1994-02-17 | 2004-03-11 | New York Blood Center, Inc. | Biologische bioadhäsive präparate, die fibrinkleber und liposomen enthalten, verfahren für ihre herstellung und verwendung |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
| US5629145A (en) | 1995-03-24 | 1997-05-13 | Organ, Inc. | Cryopreservation of cell suspensions |
| US5643192A (en) | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
| CA2238434A1 (en) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Method for obtaining retroviral vector supernatant having high transduction efficiency |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| AU4659697A (en) | 1996-10-03 | 1998-04-24 | Regents Of The University Of California, The | Cryopreservation of human adult and fetal pancreatic cells and human platelets |
| PT941116E (pt) | 1996-11-01 | 2005-05-31 | Ark Therapeutics Ltd | Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega |
| ATE307195T1 (de) | 1997-07-14 | 2005-11-15 | Osiris Therapeutics Inc | Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen |
| US20030118567A1 (en) | 1999-03-26 | 2003-06-26 | Stewart Duncan John | Cell-based therapy for the pulmonary system |
| US9585916B2 (en) | 1999-03-26 | 2017-03-07 | Northern Therapeutics Inc. | Cell based therapy for the pulmonary system |
| US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| US9320829B2 (en) | 2000-03-15 | 2016-04-26 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| EP1296724A1 (en) | 2000-06-22 | 2003-04-02 | Sam L. Austin | Bioadhesive composition and methods of preparation and use |
| AU2003297592A1 (en) | 2002-11-30 | 2004-06-23 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
| US8765813B2 (en) | 2003-12-16 | 2014-07-01 | United Therapeutics Corporation | Use of treprostinil to treat and prevent ischemic lesions |
| CA2580975A1 (en) | 2004-09-24 | 2006-03-30 | Angioblast Systems, Inc. | Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof |
| ATE499110T1 (de) | 2005-08-19 | 2011-03-15 | Univ Duke | Aus stammzellen erhaltener parakriner faktor sfrp1 zur verwendung für die verringerung zelltodes im herzgewebe |
| US20070065414A1 (en) | 2005-09-16 | 2007-03-22 | Boston Scientific Scimed, Inc. | Enhanced delivery of cells |
| US8652201B2 (en) | 2006-04-26 | 2014-02-18 | The Cleveland Clinic Foundation | Apparatus and method for treating cardiovascular diseases |
| US20090274665A1 (en) | 2006-04-27 | 2009-11-05 | Cell Therapy Technologies, Inc. | Stem Cells For Treating Lung Diseases |
| WO2008077094A2 (en) | 2006-12-19 | 2008-06-26 | Children's Medical Center Corporation | Methods for promoting neovascularization |
| KR101569168B1 (ko) | 2007-02-12 | 2015-11-13 | 안트로제네시스 코포레이션 | 태반 줄기세포를 이용한 염증 질환의 치료 |
| JP2011015609A (ja) | 2007-10-30 | 2011-01-27 | Asahikawa Medical College | 内皮前駆細胞（ｅｐｃ）の増殖・分化誘導方法 |
| PL2254586T3 (pl) | 2008-02-22 | 2015-09-30 | Agency For Science Tech And Research Astarstar | Cząstki mezenchymalnych komórek macierzystych |
| BR112013004700B1 (pt) | 2010-08-27 | 2020-12-08 | Joshua M. Hare | uso de células precursoras de células-tronco mesenquimais (msc) cd271+ |
| EP3269802B1 (en) | 2011-09-30 | 2019-10-23 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| ES2869701T3 (es) * | 2012-08-01 | 2021-10-25 | United Therapeutics Corp | Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina |
| IN2015DN00934A (enExample) | 2012-08-01 | 2015-06-12 | United Therapeutics Corp | |
| AU2014205557B2 (en) * | 2013-01-09 | 2017-08-10 | United Therapeutics Corporation | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells |
-
2017
- 2017-10-23 US US15/790,666 patent/US11571444B2/en active Active
- 2017-10-23 IL IL266175A patent/IL266175B2/en unknown
- 2017-10-23 JP JP2019521662A patent/JP7179723B2/ja active Active
- 2017-10-23 CN CN201780074352.3A patent/CN110177559A/zh active Pending
- 2017-10-23 EP EP17808627.8A patent/EP3534917B1/en active Active
- 2017-10-23 KR KR1020197014254A patent/KR102606101B1/ko active Active
- 2017-10-23 WO PCT/US2017/057863 patent/WO2018080990A1/en not_active Ceased
- 2017-10-23 ES ES17808627T patent/ES2927406T3/es active Active
- 2017-10-23 AU AU2017350732A patent/AU2017350732B2/en active Active
- 2017-10-23 CA CA3041514A patent/CA3041514A1/en active Pending
-
2022
- 2022-12-29 US US18/147,929 patent/US20230137713A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022107023A5 (enExample) | ||
| JPWO2019107530A1 (ja) | 炎症性腸疾患の治療薬 | |
| JP2017505761A5 (enExample) | ||
| JP2019206562A5 (enExample) | ||
| KR20120100962A (ko) | 신장 손상을 치료하는데 사용하기 위한 조혈 줄기 세포 | |
| JP2023520233A5 (enExample) | ||
| RU2015154737A (ru) | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности | |
| JP2019535677A (ja) | トレプロスチニルによるｍｓｃの免疫調節特性の増強 | |
| EP3302523A1 (fr) | Composition pour le traitement des lesions tissulaires | |
| Chen et al. | Current state of heart failure treatment: are mesenchymal stem cells and their exosomes a future therapy? | |
| He et al. | Exosome-equipped TNF antisense oligodeoxynucleotide or 2-deoxy-D-glucose ameliorated nonalcoholic steatohepatitis by modulating superoxide dismutase 1 in mice | |
| JP5841903B2 (ja) | 肝障害の治療または肝機能の向上のための薬剤 | |
| CN112972389A (zh) | 甘草酸纳米颗粒的合成及其在新型冠状病毒肺炎中的联合治疗应用 | |
| Song et al. | Therapeutic factors and biomaterial-based delivery tools for degenerative intervertebral disc repair | |
| CN107296806A (zh) | 丹酚酸a作为脂蛋白相关磷脂酶a2抑制剂的新用途 | |
| JP2024516172A5 (enExample) | ||
| CA2593161A1 (en) | Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries | |
| JP2017507123A (ja) | 歯原性幹細胞および遺伝的に改変された歯原性幹細胞の使用 | |
| CN118873667A (zh) | Lat1抑制剂在制备治疗动脉粥样硬化的药物中的应用 | |
| CN119499243B (zh) | 一种生物碱用于制备t细胞免疫抑制剂的应用 | |
| WO2018215571A1 (en) | Method for genetically modifying a vascularised tissue | |
| Hillestad et al. | Quinidine before direct current countershock. A controlled study | |
| JP2012056913A (ja) | 脂肪組織由来間質細胞群を含む肝炎治療剤 | |
| JP2022503847A5 (enExample) | ||
| US10328122B2 (en) | Method of treating fulminant hepatic failure using DLL4 cytokine |